Literature DB >> 29305462

Type I interferons instigate fetal demise after Zika virus infection.

Laura J Yockey1, Kellie A Jurado1, Nitin Arora2, Alon Millet1, Tasfia Rakib1, Kristin M Milano3, Andrew K Hastings4, Erol Fikrig4,5, Yong Kong6, Tamas L Horvath7, Scott Weatherbee8, Harvey J Kliman3, Carolyn B Coyne2,9, Akiko Iwasaki10,5.   

Abstract

Zika virus (ZIKV) infection during pregnancy is associated with adverse fetal outcomes, including microcephaly, growth restriction, and fetal demise. Type I interferons (IFNs) are essential for host resistance against ZIKV, and IFN-α/β receptor (IFNAR)-deficient mice are highly susceptible to ZIKV infection. Severe fetal growth restriction with placental damage and fetal resorption is observed after ZIKV infection of type I IFN receptor knockout (Ifnar1-/-) dams mated with wild-type sires, resulting in fetuses with functional type I IFN signaling. The role of type I IFNs in limiting or mediating ZIKV disease within this congenital infection model remains unknown. In this study, we challenged Ifnar1-/- dams mated with Ifnar1+/- sires with ZIKV. This breeding scheme enabled us to examine pregnant dams that carry a mixture of fetuses that express (Ifnar1+/-) or do not express IFNAR (Ifnar1-/-) within the same uterus. Virus replicated to a higher titer in the placenta of Ifnar1-/- than within the Ifnar1+/- concepti. Yet, rather unexpectedly, we found that only Ifnar1+/- fetuses were resorbed after ZIKV infection during early pregnancy, whereas their Ifnar1-/- littermates continue to develop. Analyses of the fetus and placenta revealed that, after ZIKV infection, IFNAR signaling in the conceptus inhibits development of the placental labyrinth, resulting in abnormal architecture of the maternal-fetal barrier. Exposure of midgestation human chorionic villous explants to type I IFN, but not type III IFNs, altered placental morphology and induced cytoskeletal rearrangements within the villous core. Our results implicate type I IFNs as a possible mediator of pregnancy complications, including spontaneous abortions and growth restriction, in the context of congenital viral infections.
Copyright © 2018 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29305462      PMCID: PMC6049088          DOI: 10.1126/sciimmunol.aao1680

Source DB:  PubMed          Journal:  Sci Immunol        ISSN: 2470-9468


  59 in total

1.  Cutting Edge: Fetal/Placental Type I IFN Can Affect Maternal Survival and Fetal Viral Load during Viral Infection.

Authors:  Karen Racicot; Paulomi Aldo; Ayman El-Guindy; Ja-Young Kwon; Roberto Romero; Gil Mor
Journal:  J Immunol       Date:  2017-03-06       Impact factor: 5.422

Review 2.  Regulation of antiviral T cell responses by type I interferons.

Authors:  Josh Crouse; Ulrich Kalinke; Annette Oxenius
Journal:  Nat Rev Immunol       Date:  2015-03-20       Impact factor: 53.106

3.  Evidence of Sexual Transmission of Zika Virus.

Authors:  Eric D'Ortenzio; Sophie Matheron; Yazdan Yazdanpanah; Xavier de Lamballerie; Bruno Hubert; Géraldine Piorkowski; Marianne Maquart; Diane Descamps; Florence Damond; Isabelle Leparc-Goffart
Journal:  N Engl J Med       Date:  2016-04-13       Impact factor: 91.245

4.  Gestational Stage and IFN-λ Signaling Regulate ZIKV Infection In Utero.

Authors:  Brett W Jagger; Jonathan J Miner; Bin Cao; Nitin Arora; Amber M Smith; Attila Kovacs; Indira U Mysorekar; Carolyn B Coyne; Michael S Diamond
Journal:  Cell Host Microbe       Date:  2017-09-13       Impact factor: 21.023

5.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

6.  Type I interferons regulate susceptibility to inflammation-induced preterm birth.

Authors:  Monica Cappelletti; Pietro Presicce; Matthew J Lawson; Vandana Chaturvedi; Traci E Stankiewicz; Simone Vanoni; Isaac Tw Harley; Jaclyn W McAlees; Daniel A Giles; Maria E Moreno-Fernandez; Cesar M Rueda; Paranth Senthamaraikannan; Xiaofei Sun; Rebekah Karns; Kasper Hoebe; Edith M Janssen; Christopher L Karp; David A Hildeman; Simon P Hogan; Suhas G Kallapur; Claire A Chougnet; Sing Sing Way; Senad Divanovic
Journal:  JCI Insight       Date:  2017-03-09

7.  Interferon alfa-2a therapy for life-threatening hemangiomas of infancy.

Authors:  R A Ezekowitz; J B Mulliken; J Folkman
Journal:  N Engl J Med       Date:  1992-05-28       Impact factor: 91.245

8.  Zika Virus Targets Human STAT2 to Inhibit Type I Interferon Signaling.

Authors:  Alesha Grant; Sanket S Ponia; Shashank Tripathi; Vinod Balasubramaniam; Lisa Miorin; Marion Sourisseau; Megan C Schwarz; Mari Paz Sánchez-Seco; Matthew J Evans; Sonja M Best; Adolfo García-Sastre
Journal:  Cell Host Microbe       Date:  2016-05-19       Impact factor: 21.023

Review 9.  Interferon-stimulated genes and their antiviral effector functions.

Authors:  John W Schoggins; Charles M Rice
Journal:  Curr Opin Virol       Date:  2011-12       Impact factor: 7.090

Review 10.  The decidua-the maternal bed embracing the embryo-maintains the pregnancy.

Authors:  Mayumi Mori; Agnes Bogdan; Timea Balassa; Timea Csabai; Júlia Szekeres-Bartho
Journal:  Semin Immunopathol       Date:  2016-06-10       Impact factor: 9.623

View more
  99 in total

1.  Femur-sparing pattern of abnormal fetal growth in pregnant women from New York City after maternal Zika virus infection.

Authors:  Christie L Walker; Audrey A Merriam; Eric O Ohuma; Manjiri K Dighe; Michael Gale; Lakshmi Rajagopal; Aris T Papageorghiou; Cynthia Gyamfi-Bannerman; Kristina M Adams Waldorf
Journal:  Am J Obstet Gynecol       Date:  2018-05-05       Impact factor: 8.661

Review 2.  Type III Interferons in Antiviral Defenses at Barrier Surfaces.

Authors:  Alexandra I Wells; Carolyn B Coyne
Journal:  Trends Immunol       Date:  2018-09-12       Impact factor: 16.687

3.  Profile of Akiko Iwasaki.

Authors:  Jennifer Viegas
Journal:  Proc Natl Acad Sci U S A       Date:  2018-12-03       Impact factor: 11.205

4.  A Brief Historical Perspective on the Pathological Consequences of Excessive Type I Interferon Exposure In vivo.

Authors:  Yanick J Crow; Pierre Lebon; Jean-Laurent Casanova; Ion Gresser
Journal:  J Clin Immunol       Date:  2018-09-05       Impact factor: 8.317

Review 5.  Interferons and Proinflammatory Cytokines in Pregnancy and Fetal Development.

Authors:  Laura J Yockey; Akiko Iwasaki
Journal:  Immunity       Date:  2018-09-18       Impact factor: 31.745

6.  Efficiencies and kinetics of infection in different cell types/lines by African and Asian strains of Zika virus.

Authors:  Suzane Ramos da Silva; Fan Cheng; I-Chueh Huang; Jae U Jung; Shou-Jiang Gao
Journal:  J Med Virol       Date:  2018-10-09       Impact factor: 2.327

7.  Dengue Virus Immunity Increases Zika Virus-Induced Damage during Pregnancy.

Authors:  Julia A Brown; Gursewak Singh; Joshua A Acklin; Silviana Lee; James E Duehr; Anupa N Chokola; Justin J Frere; Kevin W Hoffman; Gregory A Foster; David Krysztof; Richard Cadagan; Adam R Jacobs; Susan L Stramer; Florian Krammer; Adolfo García-Sastre; Jean K Lim
Journal:  Immunity       Date:  2019-02-05       Impact factor: 31.745

8.  Inflammatory-dependent Sting activation induces antiviral autophagy to limit zika virus in the Drosophila brain.

Authors:  Elizabeth Delorme-Axford; Daniel J Klionsky
Journal:  Autophagy       Date:  2018-11-01       Impact factor: 16.016

Review 9.  Ribosomal biogenesis as an emerging target of neurodevelopmental pathologies.

Authors:  Michal Hetman; Lukasz P Slomnicki
Journal:  J Neurochem       Date:  2018-11-12       Impact factor: 5.372

Review 10.  Protective and Pathogenic Effects of Interferon Signaling During Pregnancy.

Authors:  Rebecca L Casazza; Helen M Lazear; Jonathan J Miner
Journal:  Viral Immunol       Date:  2019-09-23       Impact factor: 2.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.